| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
125,963 |
99,182 |
$4.05M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
122,068 |
100,064 |
$2.79M |
| 64636 |
|
3,170 |
2,255 |
$2.21M |
| 64635 |
|
4,097 |
2,879 |
$1.80M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
39,316 |
29,778 |
$684K |
| 80354 |
|
51,460 |
43,646 |
$513K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
11,088 |
8,373 |
$490K |
| 64493 |
|
6,105 |
3,712 |
$473K |
| 80373 |
|
47,624 |
40,060 |
$446K |
| 80372 |
|
48,366 |
41,153 |
$424K |
| 80369 |
|
51,439 |
43,620 |
$420K |
| 80348 |
|
44,841 |
37,817 |
$411K |
| 80363 |
|
51,174 |
43,412 |
$317K |
| 80352 |
|
47,599 |
40,036 |
$297K |
| 80361 |
|
34,439 |
29,892 |
$286K |
| 80371 |
|
47,852 |
40,684 |
$280K |
| 80357 |
|
47,951 |
40,781 |
$273K |
| 80367 |
|
35,124 |
30,417 |
$255K |
| 80355 |
|
51,366 |
43,555 |
$246K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
1,083 |
825 |
$234K |
| 64494 |
|
5,848 |
3,567 |
$227K |
| 62323 |
|
1,787 |
1,333 |
$216K |
| 80359 |
|
31,949 |
27,411 |
$210K |
| 80360 |
|
35,665 |
30,898 |
$205K |
| 80338 |
|
32,098 |
27,571 |
$182K |
| 64495 |
|
4,050 |
2,264 |
$169K |
| 80366 |
|
32,089 |
27,623 |
$158K |
| 80358 |
|
14,943 |
12,629 |
$131K |
| 27096 |
|
670 |
420 |
$123K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
12,622 |
11,316 |
$117K |
| 80335 |
|
15,001 |
12,676 |
$102K |
| 80356 |
|
6,734 |
6,250 |
$84K |
| 80323 |
|
3,812 |
3,561 |
$68K |
| 80349 |
|
11,343 |
9,132 |
$50K |
| 80346 |
|
5,695 |
4,855 |
$48K |
| 80365 |
|
6,853 |
6,026 |
$41K |
| 80345 |
|
3,736 |
3,491 |
$37K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
203 |
190 |
$35K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
3,067 |
2,588 |
$34K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
2,763 |
2,377 |
$33K |
| 72141 |
|
151 |
111 |
$32K |
| 83992 |
|
5,056 |
4,703 |
$27K |
| 84403 |
|
2,834 |
2,405 |
$27K |
| 20610 |
|
937 |
686 |
$26K |
| 62321 |
|
157 |
118 |
$24K |
| 80324 |
|
3,371 |
3,021 |
$21K |
| 77002 |
|
885 |
599 |
$17K |
| 82607 |
|
2,992 |
2,524 |
$16K |
| 64451 |
|
207 |
154 |
$16K |
| 82746 |
|
2,922 |
2,468 |
$15K |
| 64634 |
|
16 |
12 |
$15K |
| 80053 |
Comprehensive metabolic panel |
3,542 |
2,841 |
$14K |
| 82977 |
|
4,255 |
3,558 |
$13K |
| 80050 |
General health panel |
766 |
760 |
$13K |
| 90791 |
Psychiatric diagnostic evaluation |
859 |
710 |
$13K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,013 |
1,593 |
$10K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
563 |
466 |
$8K |
| 64633 |
|
16 |
12 |
$8K |
| 83735 |
|
2,976 |
2,512 |
$7K |
| 99152 |
|
246 |
194 |
$7K |
| 36415 |
Collection of venous blood by venipuncture |
4,050 |
3,694 |
$6K |
| 86140 |
|
2,898 |
2,453 |
$5K |
| 84100 |
|
2,978 |
2,512 |
$5K |
| 85027 |
|
2,051 |
1,599 |
$4K |
| 99072 |
|
9,361 |
7,688 |
$4K |
| 99205 |
Prolong outpt/office vis |
42 |
36 |
$4K |
| 64483 |
|
49 |
37 |
$4K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,584 |
1,769 |
$4K |
| 64490 |
|
52 |
26 |
$3K |
| 80321 |
|
922 |
875 |
$3K |
| 99406 |
|
262 |
200 |
$3K |
| 99215 |
Prolong outpt/office vis |
37 |
28 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
688 |
438 |
$2K |
| 62370 |
|
146 |
109 |
$2K |
| 64492 |
|
52 |
26 |
$2K |
| 64491 |
|
52 |
26 |
$2K |
| 64450 |
|
58 |
27 |
$1K |
| 64640 |
|
19 |
12 |
$988.14 |
| 96130 |
|
171 |
145 |
$860.74 |
| 62369 |
|
37 |
24 |
$742.81 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
79 |
75 |
$732.36 |
| 95886 |
|
15 |
13 |
$723.94 |
| 99454 |
|
160 |
102 |
$723.89 |
| J3490 |
Unclassified drugs |
2,342 |
1,428 |
$688.03 |
| 97162 |
|
42 |
37 |
$660.15 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
3,489 |
2,282 |
$531.27 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
14 |
14 |
$498.79 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
382 |
230 |
$456.51 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
472 |
350 |
$424.96 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
123 |
115 |
$382.53 |
| 80305 |
|
96 |
83 |
$373.59 |
| 99457 |
|
174 |
125 |
$373.49 |
| 80362 |
|
796 |
748 |
$326.94 |
| 99442 |
|
136 |
87 |
$305.24 |
| 76942 |
|
36 |
24 |
$248.28 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
62 |
52 |
$238.73 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
35 |
12 |
$182.41 |
| 99443 |
|
40 |
29 |
$157.05 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
53 |
33 |
$155.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
391 |
256 |
$65.50 |
| 96136 |
|
13 |
12 |
$55.45 |
| 99441 |
|
56 |
45 |
$52.29 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
142 |
126 |
$44.70 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
2,366 |
1,515 |
$8.01 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
1,223 |
748 |
$4.83 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
60 |
43 |
$1.15 |
| G8913 |
Patient documented not to have experienced a wrong site, wrong side, wrong patient, wrong procedure or wrong implant event |
612 |
391 |
$0.03 |
| G8911 |
Patient documented not to have experienced a fall within ambulatory surgical center |
614 |
392 |
$0.03 |
| G8909 |
Patient documented not to have received a burn prior to discharge |
614 |
392 |
$0.03 |
| G8918 |
Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis |
607 |
387 |
$0.03 |
| G8915 |
Patient documented not to have experienced a hospital transfer or hospital admission upon discharge from asc |
614 |
391 |
$0.03 |
| 64454 |
|
13 |
12 |
$0.00 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
33 |
27 |
$0.00 |